NxGen MDx Issues Revised Announcement Regarding National Aetna Contract

Saturday, February 25, 2017 General News
Email Print This Page Comment
Font : A-A+

In-Network Status Confirmed While Covered Services Clarified

GRAND RAPIDS, Mich., Feb. 24, 2017 /PRNewswire/ -- NxGen MDx, a Company that provides innovative genetic testing solutions,

announced the execution of a new national Agreement with Aetna in a press release issued February 9, 2017 indicating that full-gene sequencing is covered under the new Agreement. However, it is not a covered service for Aetna members.

The Company's genetic screening and non-invasive pre-natal testing will still be available on an in-network basis for Aetna members in accordance with Aetna's Clinical Policy Bulletins beginning effective February 15, 2017.

Aetna, the third largest health plan in the United States, now provides coverage of NxGen's services via their published Clinical Policy Bulletin (CPB) following a thorough review of the Company's products.  In addition, many physicians supported the inclusion of NxGen MDx in the network due to their stated belief that NxGen MDx's suite of services are best-in-class tools and aid in informed decision-making. According to Dr. Mark Perloe, Medical Director at Georgia Reproductive Specialists in Atlanta, "Having NxGen MDx in the Aetna network allows me the flexibility to use the testing services that I believe are in my patients' best interest."

"Patients will now have in-network access to selected tests, streamlining the billing process and potentially lowering out of pocket costs depending on their benefit plan design" said Kristin Sherman, CFO of NxGen MDx. "This also removes a barrier for many health care professionals who have wanted to use our testing in the past."

About NxGen MDxNxGen MDx LLC is a leading women's health company delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their health care providers. Unlike other laboratories, NxGen MDx's technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGen MDx is located in Grand Rapids, Michigan. To learn more, visit the company's website at www.nxgenmdx.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxgen-mdx-issues-revised-announcement-regarding-national-aetna-contract-300413139.html

SOURCE NxGen MDx



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook